GSK Holds 10% Stake in Wave Life Sciences as of Dec 31, 2023

TL;DR

**GSK still owns 10% of Wave Life Sciences, signaling continued strategic interest.**

AI Summary

GSK plc, a major pharmaceutical company, filed an amended SC 13G/A on February 6, 2024, disclosing its ownership in Wave Life Sciences Ltd. As of December 31, 2023, GSK plc beneficially owned 10,790,100 ordinary shares of Wave Life Sciences Ltd., representing 10.0% of the company's total outstanding shares. This filing indicates a significant, continued stake by GSK in Wave Life Sciences, which could signal confidence in their partnership or future collaborations, potentially impacting Wave Life Sciences' stock valuation.

Why It Matters

This filing confirms GSK's substantial investment in Wave Life Sciences, suggesting a strong strategic interest that could lead to further collaboration or even acquisition, potentially boosting Wave Life Sciences' stock price.

Risk Assessment

Risk Level: low — The filing indicates a stable, significant ownership stake by a major pharmaceutical company, which generally reduces risk for the subject company.

Analyst Insight

A smart investor would view GSK's continued 10% stake as a strong vote of confidence in Wave Life Sciences, potentially signaling future strategic developments or a deeper partnership, and might consider this a positive indicator for the stock's long-term prospects.

Key Numbers

• 10,790,100 — Ordinary Shares Owned (This is the exact number of Wave Life Sciences Ltd. shares GSK plc beneficially owned as of December 31, 2023.)
• 10.0% — Percentage of Class (This represents the significant portion of Wave Life Sciences Ltd. that GSK plc controls, indicating a substantial investment.)
• December 31, 2023 — Reporting Date (This is the specific date for which the ownership stake is being reported, providing a clear snapshot of GSK's holdings.)

Key Players & Entities

• GSK plc (company) — the entity filing the SC 13G/A, reporting its ownership in Wave Life Sciences Ltd.
• Wave Life Sciences Ltd. (company) — the subject company in which GSK plc holds a significant ownership stake.
• 10,790,100 (dollar_amount) — the number of ordinary shares of Wave Life Sciences Ltd. beneficially owned by GSK plc.
• 10.0% (dollar_amount) — the percentage of Wave Life Sciences Ltd.'s ordinary shares beneficially owned by GSK plc.
• December 31, 2023 (date) — the date of the event which required the filing of this statement, reflecting the ownership as of this date.

Forward-Looking Statements

• GSK plc will maintain its significant ownership stake in Wave Life Sciences Ltd. for the foreseeable future. (GSK plc) — high confidence, target: December 31, 2024
• The continued investment by GSK plc could lead to further collaborative agreements or partnerships with Wave Life Sciences Ltd. (Wave Life Sciences Ltd.) — medium confidence, target: February 6, 2025

FAQ

Key Financial Figures

• $0 — Life Sciences Ltd. (Name of Issuer) $0 Par Value Ordinary Share (Title of Cla

Filing Documents

• wve-sc13ga_123123.htm (SC 13G/A) — 26KB
• 0001999371-24-001596.txt ( ) — 28KB

OWNERSHIP

ITEM 4. OWNERSHIP. The information in items 1 and 5 through 11 on the cover page of this Schedule 13G is hereby incorporated by reference.

OWNERSHIP OF FIVE PERCENT OR LESS OF A

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Glaxo Group Limited* 13,983,761 11.5% *Shares are held of record by Glaxo Group Limited, an indirect wholly-owned subsidiary of the Reporting Person. 13G/A1 CUSIP No. Y95308105

IDENTIFICATION AND CLASSIFICATION OF THE

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not Applicable

NOTICE OF DISSOLUTION OF GROUP

ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable

CERTIFICATIONS

ITEM 10. CERTIFICATIONS. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 6, 2024 GSK plc By: /s/ Victoria A. Whyte Victoria A. Whyte Authorized Signatory

View Full Filing

View this SC 13G/A filing on SEC EDGAR